Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1679
    +0.0022 (+0.19%)
     

  • GBP/USD

    1.2494
    -0.0017 (-0.13%)
     

  • Bitcoin GBP

    50,388.16
    -1,042.06 (-2.03%)
     

  • CMC Crypto 200

    1,304.48
    -92.06 (-6.59%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     

Shire plc : Notice of Results

GlobeNewswire

Shire to announce full year 2017 results

Dublin, Ireland - February 1, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG), will announce full year 2017 earnings on Wednesday February 14, 2018.

Results press release will be issued at:

12:00 GMT / 07:00 EST

Investor conference call time:

14:00 GMT / 09:00 EST

Live conference call for investors:
Flemming Ornskov, MD, M.P.H., Chief Executive Officer and John Miller, Interim Chief Financial Officer will host the investor and analyst conference call at 9:00 am EST / 14:00 GMT.

The details of the conference call are as follows:

UK dial in:

0800 358 9473 or +44 333 300 0804

US dial in:

1 855 857 0686 or 1 631 913 1422

International Access Numbers:

Click here

Password/Conf ID:

76960651#

Live Webcast:

Click here

Replay:
A replay of the presentation will be available for two weeks by phone and by webcast for three months. Replay information can be found on the Investor Relations section of Shire`s website at http://investors.shire.com/.

ADVERTISEMENT

For further information please contact:

Investor Relations

Christoph Brackmann

christoph.brackmann@shire.com

+41 795 432 359

Sun Kim

sun.kim@shire.com

+1 617 588 8175

Robert Coates

rcoates@shire.com

+44 203 549 0874

Media

Lisa Adler

lisa.adler@shire.com

+1 617 588 8607

Katie Joyce

kjoyce@shire.com

+1 781 482 2779

About Shire

Shire is the global leader in serving patients with rare diseases. We strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.

We feel a strong sense of urgency to address unmet medical needs and work tirelessly to improve people`s lives with medicines that have a meaningful impact on patients and all who support them on their journey.

www.shire.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Shire plc via GlobeNewswire
HUG#2165443